Billionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You?
Julian and Felix Baker of the $15.6 billion hedge fund Baker Bros. Advisors are well-known for their uncanny ability to unearth hidden gems in biotech and biopharma. So when I noticed that the dynamic duo purchased a noteworthy 2 million shares of the beaten-down vaccine maker Novavax (NASDAQ: NVAX) in the second quarter of 2017, it piqued my interest to say the least.
The Baker Bros., after all, have repeatedly picked some of the top-performing biotech stocks over the past six years, and they've also successfully mined the ultra-risky landscape of clinical setbacks to produce some truly astounding gains.
Image Source: Getty Images.
Source: Fool.com
Acadia Pharmaceuticals Aktie
17,22 €
-0,64 %
Starkes Kaufinteresse bei Acadia Pharmaceuticals, mit einer großen Anzahl an Buy- und wenigen Sell-Einschätzungen.
Das Kursziel von 31 € für Acadia Pharmaceuticals bedeutet eine deutliche Steigerung von über 50% gegenüber dem aktuellen Kurs von 17.22 €.
